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Abstract
Background:  Tumor spread beyond the peritoneal cavity in cases of papillary serous
adenocarcinoma of the unknown primary (CUP) is a rare late event and carries a poor prognosis.
Case presentation: A 71-year-old female was referred to our hospital because of a large right
inguinal tumor with biopsy evidence of carcinoma as well as an elevated serum CA125 (cancer
antigen 125). She underwent complete resection of the right inguinal tumor and multiple pelvic
tumors, which involved the rectum, ovary and uterus. Pathological examination revealed the
tumors to be metastases of a papillary serous adenocarcinoma with a psammoma body of CUP. On
the 28th postoperative day, newly developed asymptomatic small left inguinal node metastases in
the setting of a normal CA125 level were removed. Four and a half years after the primary
resection, the CA125 level increased again and newly developed asymptomatic metastases were
found in the right deep inguinal nodes and extirpated at that time. All surgical resections followed
the modified FAM (5FU, Adriamycin; ADM, MMC) regimen, including protracted dairy oral
administration of UFT or 5'-FDUR, Cimetidine and PSK (protein-bound polysaccharide K) as an
immunomodulator or biological response modifier in conjunction with intermittent one-day
continuous infusion (ADM+MMC) or intermittent single bolus injection of ADM+MMC. At
present, the patient has been living in good health for almost 7 years with no evidence of relapse.
Conclusion:  Aggressive resection surgery followed by effective adjuvant chemotherapy is
necessary for surviving long time without relapse of poorly prognostic patients with metastases
outside of the abdominal cavity from peritoneal papillary serous adenocarcinomas.
Background
Despite recent advances in diagnostic imaging and molec-
ular pathology, CUP accounts for about 3 % of all malig-
nant neoplasms, which represent a group of
heterogeneous tumors sharing unique clinical characteris-
tics of metastatic epithelial cancers with no identifiable
origin even on autopsy [1]. The heterogeneity of CUPs in
their clinical presentations, histologic types and natural
histories has rendered accurate diagnosis and appropriate
treatment strategies difficult. Female patients with perito-
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neal papillary serous carcinomatosis form a subset of
patients who respond favorably to cisplatin-based chem-
otherapy; however, metastases outside of the peritoneal
cavity are unusual and carry a dismal prognosis [2,3].
There is no standard chemotherapeutic regimen for
repeated metastases outside of the peritoneal cavity in
cases of peritoneal papillary serous adenocarcinomatosis
[4].
Herein, we present a female patient with repeated bilateral
inguinal lymph node metastases from peritoneal papil-
lary serous adenocarcinomatosis of CUP, who is alive and
well almost 7 years after the initiation of therapy involv-
ing multiple resection surgeries and unique adjuvant
chemoimmunotherapy.
Case presentation
Present history and preoperative examination
A 71-year-old female was admitted to our hospital with a
large right inguinal tumor (5 cm in diameter) on June 2,
1999. She complained of inguinal mass increasing in size
for the 4 months preceding admission. She had a past his-
tory of an appendectomy for acute appendicitis 16 years
previous to admission. No abnormalities were found in
her complete blood and biochemistry profiles. Serum car-
cinoembryonic antigen (CEA), carbohydrate antigen 19–
9 (CA19-9), squamous cell carcinoma antigen (SCC) were
all within normal limits, but CA125 was elevated to 360
U/ml at hospitalization. Ultrasonography, CT-scan and
MRI demonstrated not only a right inguinal tumor, but
also showed large pelvic tumors (Fig. 1A&1B). The uterus
A. CT demonstrated a large lump of inguinal tumor (arrow) on the right femoral vessels Figure 1
A. CT demonstrated a large lump of inguinal tumor (arrow) on the right femoral vessels. B. CT showed tumors with 3 cm in 
diameter locates between urinary bladder and uterus (solid arrow) and a bigger (5 cm) tumor (hallow allow), showing invasive 
growth to the adjacent uterus and rectum. C. Right inguinal tumor is circumscribed fairly well and measured 42 × 25 × 12 mm 
in size. The cut surface is swell up and reddish-white, and had hemorrhagic and necrotic foci. D. A lump of intra-pelvic tumors 
removed by total hysterectomy (U) with salpingo-oophorectomy and a partial resection of the rectum wall (R) at the rectosig-
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was myomatous, but no evident tumor mass was identi-
fied elsewhere by whole body CT, MRI and scintigraphy.
Endoscopic examinations of the esophagus, gastrointesti-
nal and colorectal tracts did not reveal any sign of malig-
nant tumor. The tumor growth pattern was rather
expansive into the adjacent urinary bladder, uterus and
rectum. She had several asymptomatic tiny gallbladder
stones. She underwent complete tumor resection of the
right inguinal tumors with salpingo-oophorectomy and
partial resection of the rectal wall at the recto-sigmoid
junction on July 1st, 1999.
CT on the 23rd postoperative day demonstrated new
small asymptomatic inguinal tumors adjacent to the left
external iliac artery. The diameter of those tumors was 15
mm and 12 mm, respectively. Those tumors were extir-
pated completely on July 29, 1999.
Operative procedures and findings
The right inguinal tumor, approximately 4.5 × 5 × 4 cm in
diameter, was relatively well circumscribed by the right
inguinal ligament, and right external iliac artery and vein,
which are supplying and draining tumor blood flow. After
A. Microscopic photograph (HE, X200) of the right inguinal tumor of the first resection Figure 2
A. Microscopic photograph (HE, X200) of the right inguinal tumor of the first resection. Cancer cells had marked eosinophilic 
cytoplasm and moderately atypical nucleus. Cancer cells show micropapillary growth pattern into the lymphatic node and many 
Psammoma bodies (hallow arrow) are evident. These findings indicate metastasis of serous papillary adenocarcinoma. B. Micro-
scopic photograph (HE, X200) of the ovarium. Almost whole ovarial tissue had been replaced by fibrothecoma (FT) without 
carcinoma cells (C), but tumor cells invaded from the out side of the ovary. C. Microscopic photograph (HE, X40) of the rec-
tum. Adenocarcinoma cells infiltrated from the serosal side to the submucosal layer (hallow arrow), however, no cancer cells 
had reached to the mucosal layer (M). D. Microscopic photograph (HE, X200) of the right inguinal lymph node of the 3rd 
resection. Metastasized serous papillary adenocarcinoma cells are growing in micropapillary pattern into the lymphatic tissue 
similarly as Fig. 2-A. Hallow allow represents Psammoma body.International Seminars in Surgical Oncology 2006, 3:22 http://www.issoonline.com/content/3/1/22
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extirpation of the inguinal tumors, the intra-pelvic tumors
were removed completely by total hysterectomy with salp-
ingo-oophorectomy and a partial resection of the rectum
at the rectosigmoid junction (Fig. 1C&1D). There was no
direct invasion of the tumor into the urinary bladder and
there was no evidence of remaining tumor in the abdom-
inal cavity.
Pathologic findings and diagnosis
Grossly, the right inguinal tumor was elliptical and well
circumscribed, measuring 42 × 25 × 12 mm in size. The
cut surface of the solid tumor was swollen and reddish-
white, with hemorrhagic and necrotic foci (Fig. 1C). His-
tologically, the tumor was encapsulated by dense fibrous
tissue. The configurations of the individual tumor cells
were cuboidal or polygonal and growing in a micropapil-
lary pattern. The tumor cells had marked eosinophilic
cytoplasm and moderately atypical nuclei. Many psam-
moma bodies [5] were recognized and these findings
facilitated the diagnosis of metastatic papillary serous ade-
nocarcinoma (Fig. 2A). Almost all of the ovarian tissue
had been replaced by a fibrothecoma without carcinoma
cells, but tumor cells invaded from out side of the ovary
(Fig. 2B). There were 4 leiomyomas within the uterus, but
no cancer cells were recognized anywhere in the uterus.
On the rectum wall, carcinoma cells infiltrated from the
serosal side to the submucosal layer; however, no cancer
cells had reached the mucosal layer (Fig. 2C).
Postoperative course and adjuvant therapy
Her postoperative course was uneventful, except for the
early detection of the left inguinal node metastasis by CT
on the 23rd postoperative day. This tumor was extirpated
promptly and postoperative imaging procedures con-
firmed that no tumor remained anywhere in the body.
Pathologic examinations revealed lymph node metastasis
from a papillary serous adenocarcinoma (Fig. 2D). Preop-
eratively, daily oral administration of UFT (450 mg/day)
Cimetidine (H2 receptor antagonist; 600 mg/day) and
PSK (3 g/day) was started. We used Cimetidine not only
as an anti-ulcer drug, but also as an immunomodulator or
biological response modifier with the hope of eradicating
possible microscopic residual cancer cells [6-8]. PSK was
used as an immunomodulator against possible remaining
adenocarcinoma cells somewhere in the body of this
patient [9,10]. In order to increase the anti-tumor effect as
well as decrease the toxicity, we tried intravenous single-
day continuous infusion of low dose combination chem-
otherapy through a port implanted on the right upper
chest wall with an access catheter (Groshong®) to the
superior vena cava by way of the right subclavian vein. A
portable elastomeric infusion system filled with 50 ml
saline dissolution of Mitomycin C (MMC; 6 mg) and Adri-
amycin (ADM; l0mg) was applied every other week at an
outpatient clinic. Three months after we changed from
UFT to 5'-FDUR (600 mg/day) because MMC may be
more effective with 5'-FDUR (due to stronger inductive
activity of thymidine phosphorylase (dThdPase) in tumor
tissues [11,12].
The implanted port and access catheter were removed two
years later. The serum tumor markers CA-125, CEA and
CA19-9 were checked every month and image diagnostic
screening by CT and US were carried out every three
months during 4 postoperative years, however, no sugges-
tive signs of relapse had been found anywhere in the
body. However, from 4.5 years after the last surgery, the
serum level of CA-125 had gradually elevated to 140.5 U/
ml and the CT scans demonstrated newly developed
asymptomatic single tumor growth (25 × 20 mm) on the
right deep inguinal node (Fig. 3), though no evident
tumor was found anywhere else in the body. Complete
tumor removal was carried out and the serum CA125
decreased to within the normal range (Fig. 3). Pathologic
examination revealed that papillary serous adenocarci-
noma cells were growing in the lymph node in a micro-
papillary pattern and many psammoma bodies were
recognized (Fig. 2D). Findings of US, CT and the tumor
markers have suggested no relapse of disease and oral 5'-
DFUR administration was discontinued at the 6th year,
but oral Cimetidine and PSK have been continued. No
adverse effects were encountered at any time during the
clinical course (Fig. 3) and the patient is living well, dis-
ease-free almost 7 years after the primary tumor resection.
Changes of CA125 and white blood cell count after treat- ment Figure 3
Changes of CA125 and white blood cell count after treat-
ment. The serum level of CA125 ( ). The white 
blood cell number ( ) Daily oral administration 
of UFT (450 mg/day);   or 5'-FDUR (600 mg/day);   
plus Cimetidine (H2 receptor antagonist; 600 mg/day) and 
PSK (3 g/day). Continuous infusion and iv-injection; see text.International Seminars in Surgical Oncology 2006, 3:22 http://www.issoonline.com/content/3/1/22
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Discussion
Despite modern imaging technology, including Positron
Emission Tomography (PET) scanning, the primary site
remains unknown in patients with metastatic CUP, even
on autopsy. Metastatic CUP represents a heterogeneous
group in terms of clinical presentation, histology and pre-
sumably biology. Lymph node involvement, the number
of metastatic organ sites, hepatic involvement, and tumor
histology have been reported as significant independent
prognostic factors [2]. Although the histologic features of
our case presented a papillary configuration and psam-
moma bodies in all of the surgical specimens, no primary
site was found in the body or in the ovaries. Taking into
account the fact that the epithelial layer of the ovary and
the peritoneum share a common origin from the coe-
lomic epithelium embryonically and that repeated eleva-
tions of the serum CA19-9 level occurred whenever
metastasis had occurred in our case, it is plausible that
papillary serous carcinoma of the peritoneum is an analog
with ovarian carcinoma or an extraovarian primary perito-
neal carcinoma [3,14]. Clinical experiences in treating
patients with inguinal nodes metastases of female perito-
neal papillary serous carcinomas have been reported
infrequently and there is a lack of a standard chemothera-
peutic regimen for this unusual and poor prognostic dis-
ease [2,15]. Cisplatin-based chemotherapy might be a
choice in our case, given that favorable response rates
[3,14,15] have been reported in female peritoneal papil-
lary serous carcinoma cases if metastases outside the peri-
toneal cavity have not been present. However, we chose
modified FAM, because a regimen including 5-FU, ADM
and MMC have shown some valuable activity in many
adenocarcinomas of the gastrointestinal tract, pancreas,
lung and breast, etc. Instead of 5-FU we used UFT and 5'-
DFUR, which are synthesized fluoropyrimidine prodrugs
of 5-FU for oral administration and have been designed to
improve the delivery of 5-FU. Both are intended to
increase the anti-cancer efficacy and reduce the toxicity by
slow conversion of the drug to fluorouracil through the
cytochrome P-450 metabolic pathway [16] in the former
and by dominant delivery of fluorouracil in cancer tissues
in the latter [12]. We tried reciprocal enhancement of anti-
tumor effects of 5'-DFUR and MMC with anticipation of
less toxicity. MMC was used not only tumor cell killing,
but also as an up-regulator of dThdPase, which is an
essential enzyme to convert 5'-DFUR to 5-FU located
more amount than in the non-cancerous tissue [12].
Cimetidine and PSK may have favorable effects as an
immunomodulator or biological response modifiers to
kill some microscopic residual cancer cells and to prevent
possible formation of new metastases by inhibiting cancer
cell adhesion to endothelial cells [6-10].
Conclusion
Female patients with metastases to the inguinal nodes
from peritoneal papillary serous carcinomas of CUP are
rare and have poor prognoses. There is no standard effec-
tive chemotherapeutic regimen for these patients. How-
ever, complete tumor removal followed by appropriate
chemotherapy can lead to long-term survival even if the
patient had nodal metastases beyond the abdominal cav-
ity. Our modified FAM using protracted intermittent infu-
sion of low dose MMC/ADM combined with oral UFT/5'-
FDUR with PSK/Cimetidine may prove to be an efficient
chemotherapeutic regimen with low toxicity, and which is
amenable to good compliance.
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